The 2024 call for applications will be launched very shortly. Are you a young/recently qualified clinician interested in learning more about HD? Click here for further details. […]
Рубрика: Uncategorized
EHDN Newsletter – 50th edition
The EHDN newsletter (archive) aims to communicate the network’s activities and other developments of interest in the field of Huntington’s disease to the lay community, healthcare professionals and scientists. It appears three times a year (March 1, July 1, Nov 1). To receive EHDN news going forward, please subscribe to the EHDN news at the […]
EHDN Plenary Meeting and Enroll-HD Congress Strasbourg 2024 — Save the Date!
Dear Friends of EHDN, It is our pleasure to cordially invite you to the EHDN Plenary Meeting and Enroll-HD Congress Thursday 12th to Saturday 14th September, 2024 Strasbourg, France The EHDN and Enroll-HD 2024 is a collaborative event combining the EHDN Plenary Meeting and the Enroll-HD Congress. The event will be held across […]
Sign up for the Prilenia–EHDN Meeting!
EHDN will be hosting a virtual meeting to consider the emerging result of the Proof-HD study on Monday October 9th at 5pm CET (4pm GMT). The meeting is aimed at professionals, but all are welcome. […]
Video Postcard from CHDI HD Therapeutics Conference
[…]
EHDN Virtual Forum for Working Groups and Task Forces — registration open
We are delighted to announce the EHDN Virtual Forum for Working Groups and Task Forces that will take place on September 15, 2023 (12:00-15:40 CEST — Central European Summer Time) via Zoom. Agenda_EHDN WG and TF Virtual Meeting The goal of the Forum is to make activities of the EHDN Working Groups (WGs) and Task […]
EHDN Newsletter – 49th edition
The EHDN newsletter (archive) aims to communicate the network’s activities and other developments of interest in the field of Huntington’s disease to the lay community, healthcare professionals and scientists. It appears three times a year (March 1, July 1, Nov 1). To receive EHDN news going forward, please subscribe to the EHDN news at the […]
Good news from PTC and uniQure!
On 21 June 2023, positive findings from both PTC Therapeutics and uniQure were shared with the HD community on their respective huntingtin (HTT)-lowering approaches to treating HD. PTC’s interim 12-week data from the global PIVOT-HD trial of PTC518 showed dose-dependent lowering of HTT protein levels, confirmed the intended exposure in cerebrospinal fluid, and indicated a […]
CHDI’s 18th Annual HD Therapeutics Conference — scientific presentations
CHDI’s 18th Annual HD Therapeutics Conference took place April 24 – 27, 2023, in Dubrovnik, Croatia, to allow more Europe-based colleagues to attend. This unique conference series focuses on drug discovery and development for Huntington’s disease, drawing participants from the biotech and pharmaceutical sectors as well as academia. The conference is intended as a forum […]
EAN CONGRESS BUDAPEST 2023 — JULY 1-4
9th Congress of the European Academy of Neurology […]